Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2024年2月2日 - 8:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 1, 2024
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
![](https://www.sec.gov/Archives/edgar/data/353278/000117184324000528/logo.jpg)
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 1 February 2024
— This company announcement discloses the data of the transaction(s) made in Novo Nordisk
shares by the company’s board members, executives and their associated persons in accordance
with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have
reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their
behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading
in shares issued by Novo Nordisk.
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Liselotte
Sofie Hyveled |
2 |
Reason
for the notification |
a) |
Position/status |
Member
of the Board of Directors |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details
of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details
of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
2,028
shares |
|
|
|
d) |
Aggregated information
· Aggregated volume
· Price |
2,028 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Liselotte
Sofie Hyveled |
2 |
Reason
for the notification |
a) |
Position/status |
Member
of the Board of Directors |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details
of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details
of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
2,042
shares |
|
|
|
d) |
Aggregated information
· Aggregated volume
·
Price |
2,042 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Lars
Fruergaard Jørgensen |
2 |
Reason for the notification |
a) |
Position/status |
President
and CEO |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
131,760
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
131,760 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details of the
person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Lars
Fruergaard Jørgensen |
2 |
Reason for the notification |
a) |
Position/status |
President
and CEO |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
149,422
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
149,422 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details of the
person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Maziar
Mike Doustdar |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
41,488
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
41,488 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Maziar
Mike Doustdar |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
48,791
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
48,791 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Maziar
Mike Doustdar |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Sale
of shares |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
756.84 |
2,166
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
2,166 shares
DKK 756.84 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Nasdaq
Copenhagen |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Maziar
Mike Doustdar |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Sale
of shares |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
756.84 |
2,548
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
2,548 shares
DKK 756.84 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Nasdaq
Copenhagen |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Ludovic
Helfgott |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
37,346
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
37,346 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Ludovic
Helfgott |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
36,664
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
36,664 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Ludovic
Helfgott |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Sale
of shares |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
756.84 |
11,620
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
11,620 shares
DKK 756.84 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Nasdaq
Copenhagen |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Ludovic
Helfgott |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Sale
of shares |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
756.84 |
11,407
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
11,407 shares
DKK 756.84 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Nasdaq
Copenhagen |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Karsten
Munk Knudsen |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
41,254
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
41,254 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Karsten
Munk Knudsen |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
43,402
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
43,402 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Douglas
Langa |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
41,488
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
41,488 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Douglas
Langa |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other transaction (transfer of shares
in
accordance with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
39,755
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
39,755 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Douglas
Langa |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Sale
of shares |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
756.84 |
22,027
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
22,027 shares
DKK 756.84 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Nasdaq
Copenhagen |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Douglas
Langa |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Sale
of shares |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
756.84 |
19,878
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
19,878 shares
DKK 756.84 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Nasdaq
Copenhagen |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Douglas
Langa |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President, head of North America Operations |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
ADRs |
|
|
Identification
code |
NVO |
|
|
b) |
Nature
of the transaction |
Purchase
of ADRs |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
1,092.25 |
16.31
ADRs |
|
|
|
d) |
Aggregated information
· Aggregated volume
·
Price |
16.31 ADRs
DKK 1,092.25 |
e) |
Date
of the transaction |
2023-04-10 |
f) |
Place
of the transaction |
New
York Stock Exchange |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Douglas
Langa |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President, head of North America Operations |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
ADRs |
|
|
Identification
code |
NVO |
|
|
b) |
Nature
of the transaction |
Purchase
of ADRs |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
1,275.49 |
10.42
ADRs |
|
|
|
d) |
Aggregated information
· Aggregated volume
·
Price |
10.42 ADRs
DKK 1,275.49 |
e) |
Date
of the transaction |
2023-09-01 |
f) |
Place
of the transaction |
New
York Stock Exchange |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Martin
Holst Lange |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
16,780
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
16,780 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Martin
Holst Lange |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
33,600
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
33,600 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Tania
Sabroe |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
7,763
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
7,763 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Tania
Sabroe |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
13,220
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
13,220 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Tania
Sabroe |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Sale
of shares |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
756.84 |
413
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
413 shares
DKK 756.84 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Nasdaq
Copenhagen |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Tania
Sabroe |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Sale
of shares |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
756.84 |
702
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
· Price |
702 shares
DKK 756.84 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Nasdaq
Copenhagen |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Marcus
Schindler |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
16,780
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
16,780 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Marcus
Schindler |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
33,600
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
33,600 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Camilla
Sylvest |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
41,254
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
41,254 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Camilla
Sylvest |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
43,402
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
43,402 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Henrik
Ehlers Wulff |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
43,563
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
43,563 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name
of the Board member/Executive/Associated Person |
Henrik
Ehlers Wulff |
2 |
Reason for the notification |
a) |
Position/status |
Executive
Vice President |
b) |
Initial
notification/Amendment |
Initial
notification |
3 |
Details of the issuer |
a) |
Name |
Novo
Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
Identification
code |
Novo
Nordisk B DK0062498333 |
|
b) |
Nature
of the transaction |
Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) |
c) |
Price(s)
and volume(s) |
|
|
Price(s) |
Volume(s) |
|
DKK
0.00 |
45,834
shares |
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
45,834 shares
DKK 0.00 |
e) |
Date
of the transaction |
2024-01-31 |
f) |
Place
of the transaction |
Outside
a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: www.novonordisk.com CVR no: 24 25 67 90 |
| | Company announcement No 8 / 2024 |
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered
in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering
scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs
about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen
(Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram,
X, LinkedIn and YouTube.
Contacts for further information
Media: |
|
|
|
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com |
Elizabeth DeLuca (US)
+1 609 580 9868
edel@novonordisk.com |
|
|
Investors: |
|
|
|
Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com |
Frederik Taylor Pitter
+45 3075 8259
fptr@novonordisk.com |
|
|
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com |
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com |
|
|
Sina Meyer
+45 3079 6656
azey@novonordisk.com |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet:
www.novonordisk.com
CVR no:
24 25 67 90 |
|
|
Company announcement No 8 / 2024 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: February 1, 2024 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
過去 株価チャート
から 6 2024 まで 7 2024
Novo Nordisk (PK) (USOTC:NONOF)
過去 株価チャート
から 7 2023 まで 7 2024